NEUWAY Pharma

About:

NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases

Website: http://www.neuway-pharma.com

Top Investors: KfW, Wellington Partners

Description:

NEUWAY Pharma is committed to bringing transformative neuropharmaceuticals across the blood-brain barrier through its EnPC®, the drug delivery technology based on a natural derived protein capsule. In addition to advancing its proprietary pipeline, the company aims to be a partner of choice in particular for antibody and mRNA drug developers stymied by the hurdles of delivering these and other drug modalities into the brain and CNS tissue. Operating as a drug developer and a delivery expert, NEUWAY will demonstrate the value of its technology through its internal orphan neurological disease pipeline and partnered programs.

Total Funding Amount:

5.85M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Bonn, Nordrhein-Westfalen, Germany

Founded Date:

2014-04-01

Founders:

Heiko Manninga, Stephan Rapp

Number of Employees:

11-50

Last Funding Date:

2015-10-29

IPO Status:

Private

Industries:

© 2025 bioDAO.ai